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Abstract: The use of doxorubicin (DOX), one of the most effective antitumor molecules in 
the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe 
side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles 
(PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing 
a reduction of the effective dose required for antitumor activity and consequently the level of 
associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug 
entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed 
in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in 
vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method 
yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in 
vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC
50
) of DOX-
loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, 
respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a 
tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing 
DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great 
potential for improving the efficacy of DOX therapy against advanced breast cancers.
Keywords: biodegradable polymer, carcinoma, cytotoxicity, chemotherapeutic drug, drug 
delivery, nanopolymer
Introduction
Breast cancer is the most common malignancy affecting women in the world. Thirty 
percent of patients eventually develop an untreatable metastatic disease, their average 
life expectancy being no more than 3 years.1 At present, systemic chemotherapy is 
considered the standard strategy against metastatic breast cancer. Despite the impor-
tant advances in breast cancer therapy, including the development of new molecules 
(eg, trastuzumab, fulvestrant, eribulinmesylate), combinations of well-established 
drugs continue to be the first-line therapy against the malignant disease.2 Doxorubicin 
(DOX)-based regimens, due to the molecule’s high antitumor efficacy, are one of the 
most interesting approaches toward improving the level of clinical success in treating 
metastatic breast cancers. However, DOX-based chemotherapy is characterized by poor 
tumor selectivity plus severe (dose-limiting) side effects in healthy tissues and cells.3,4 
Furthermore, DOX can lead to drug resistance in breast cancer cells, which may be 
another pertinent cause of chemotherapy failure.5 Therefore, new research efforts are 
needed to reduce the effective dose required for antitumor activity, the toxicity, and 
the drug resistance associated with DOX in such chemotherapy programs.6
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therapies against advanced breast cancers, while also mini-
mizing the toxicity associated with doxorubicin’s activity.
Materials and methods
Materials
All chemicals used were of analytical grade from Sigma-
Aldrich Chemical Co. (Spain), except for DOX hydrochloride 
(purchased from Dr M Damas, San Cecilio Hospital, 
Granada, Spain), and butylcyanoacrylate (generous gift from 
Henkel Loctite, Ireland).
Preparation of poly(butylcyanoacrylate) 
nanoparticles
PBCA NPs were synthesized following the well-known 
emulsion/polymerization procedure for butylcyanoacrylate 
monomers in an aqueous solution.18,19 Briefly, a 1% (w/v) 
acetonic solution of the monomer was added dropwise, under 
stirring at 1,200 rpm, to 10 mL of an aqueous polymerization 
medium containing 10-4 N HNO
3
 and the stabilizing agent 
Pluronic® F-68 (Sigma-Aldrich, St Louis, MO, USA) (1%, 
w/v). The mixture was maintained under polymerization 
conditions for 3 hours, after which the medium was finally 
neutralized with 10 μL of an aqueous NaOH (10-1 M) solution 
to ensure total consumption of the monomer. The remaining 
acetone was then fully evaporated using a BuchiRotavapor® 
(BÜCHI Labortechnik AG, Flawil, Switzerland) rotary 
evaporator to obtain an aqueous suspension of PBCA NPs. 
Finally, the nanoparticulate system was cleaned by subjecting 
it to repeated cycles of centrifugation (60 min at 10,700 rpm 
using a Centrikon T-124 high-speed centrifuge, Kontron, 
France) and redispersion in water, until the conductivity of 
the supernatant was 10 μS/cm.
loading to the polymeric nanoplatform 
with doxorubicin
The polymeric NPs were loaded with antitumor drug by: 
1) DOX entrapment within the (nano-)matrix; and 2) DOX 
surface adsorption onto previously prepared NPs. DOX 
entrapment/adsorption within/onto the NPs was assessed 
through UV–Vis spectroscopy by determining the amount 
of drug remaining in the supernatant solutions (see below), 
which were obtained by filtering the nanoparticulate suspen-
sions through a 0.1 μm membrane filter, after the entrapment/
adsorption process. No DOX adsorption on the filter mem-
brane was determined spectrophotometrically.
DOX entrapment involved the preparation of an aque-
ous polymerization medium, containing 10-4 N HNO
3
 
and Pluronic® F-68 (1%, w/v) (Sigma-Aldrich), and the 
In this context, the use of nanotechnology may be a 
promising strategy to improve DOX efficacy and safety. 
Drug-delivery nanoplatforms have been formulated to protect 
the antitumor agents that are loaded onto them from in vivo 
metabolization and elimination (thus optimizing the phar-
macokinetic profile of the antitumor agent), and to increase 
drug accumulation at the site of the tumor, thereby reducing 
the drug dose needed to obtain a greater antitumor effect and 
minimizing toxicity.7 Poly(alkylcyanoacrylates) have been 
used as promising nanoplatforms in targeted tissue/cell drug 
delivery, because of their well-known biodegradability and 
low toxicity in chronic treatments (multiple dosing), good tol-
erance, and biocompatibility.8–11 Furthermore, cell recovery 
after the metabolization of poly(alkylcyanoacrylate)-based 
nanoparticles (NPs) occurs easily in vivo, thanks to the 
very low contact time between healthy tissues and the 
NP biodegradation products that are carried away from 
the degradation site by the blood flow.12 These nanocar-
riers have been engineered for the efficient delivery of 
numerous anticancer drugs to the tumor site (targeted drug 
delivery), thus increasing the patient survival rate.13 In this 
regard, they have demonstrated a promising capacity to 
reverse the multidrug resistance mechanisms developed by 
malignant cells. For instance, the adsorption of drug-loaded 
poly(alkylcyanoacrylate) NPs onto the surface of cancer cells, 
along with the formation of drug–poly(cyanoacrylic acid) ion 
pairs (as polymer degradation occurs), has been described 
as preventing drug recognition by the P-glycoprotein.14 
Some authors have produced a large volume of particularly 
interesting work with respect to the development of DOX-
loaded poly(alkylcyanoacrylate) NP. However, their work is 
entirely focused on the application of such nanoplatforms to 
glioblastoma models.8,15–17 To the best of our knowledge, the 
possibilities of these DOX-loaded polymeric nanoplatforms 
have not been fully investigated in other cancer models, eg, 
that of breast cancers.
The present work, therefore, is devoted to the engineering 
of DOX-loaded poly(butylcyanoacrylate) (PBCA) NPs with 
the aim of optimizing DOX therapies used against breast 
cancers. To that end, the best formulation conditions have 
been investigated. Compared with the free drug, our nano-
particulate DOX delivery system gave rise to a significant 
enhancement of the in vitro antiproliferative efficacy of DOX 
molecules. In addition, in vivo experiments demonstrated that 
the DOX-loaded PBCA nanoparticulate formulations clearly 
reduced tumor growth without evidence of an associated 
systemic toxicity. Therefore, this (nano-)formulation may 
be a promising candidate for improving the efficacy of DOX 




DOX-loaded PBca nanoparticles breast cancer treatment
subsequent dropwise addition of an acetonic solution of the 
butylcyanoacrylate monomer (1%, w/v) containing increas-
ing concentrations of DOX (10-4, 5×10-4, 10-3, 5×10-3, and 
10-2 M). All other steps previously described to prepare the 
PBCA NPs remained unchanged. Finally, DOX surface 
adsorption was performed at 25.0°C±0.5°C by combining 
suspensions of PBCA NPs (≈2%, w/v) with aqueous DOX 
solutions of known concentrations (10-4, 5×10-4, 10-3, 5×10-3, 
and 10-2 M). The suspensions were then stirred (50 rpm) for 
24 hours. All experiments were performed in triplicate.
characterization methods
The geometry of the NPs was deduced from scanning 
electron microscopy images (Zeiss DSM 950 scanning 
electron microscope, Germany). Before taking images, a 
dilute aqueous NP suspension (≈0.1%, w/v) was sonicated 
for 5 minutes, and then drops of the suspension were placed 
on copper grids with Formvar film. The grids were then dried 
in a convection oven at 35.0°C±0.5°C.
Mean particle diameters were also determined in triplicate 
at 25.0°C±0.5°C by photon correlation spectroscopy (PCS) 
(Malvern Autosizer® 4700, Malvern Instruments Ltd., 
Malvern, UK), with the scattering angle set at 60°. Mea-
surements were made after suitably diluting the aqueous NP 
dispersions (≈0.1%, w/v). The stability of the DOX-loaded 
PBCA NPs was assessed by measuring both their size and 
DOX loading values after 1 month of storage in water at 
4.0°C±0.5°C. The surface electrical properties of the PBCA 
NPs (in a ≈0.1% w/v aqueous suspension) were examined 
by electrophoresis (Malvern Zetasizer 2000 electrophoresis 
device, Malvern Instruments Ltd.) at pH 4 (adjusted with the 
addition of 10-4 N HNO
3
) and in a 10-3 M KNO
3 
solution. 
Measurements were performed at 25.0°C±0.5°C, after the 
DOX solution and PCBA NP suspension had been mixed 
under mechanical stirring (200 rpm) for 24 hours at the same 
temperature. The experimental uncertainty of the measure-
ments was less than 5%. The O’Brien and White theory was 
used to convert the electrophoretic mobility (u
e
) data into 
zeta potential (ζ ) values.20
UV–Vis absorption measurements (8500 UV–Vis Dinko 
spectrophotometer, Dinko, Spain) to determine DOX con-
centration in all the systems investigated were conducted at 
the maximum absorbance wavelength (481 nm), using quartz 
cells of 1 cm path length. Good linearity was observed at this 
wavelength, and the method was validated and verified for 
accuracy, precision, and linearity in all conditions tested. The 
reproducibility of the drug solutions’ UV–Vis absorbance 
spectra was assured throughout the time period required 
for the experiments performed in this work by wrapping 
all glassware with aluminum foil to protect them against 
ambient light. DOX entrapment/adsorption measurements 
were carried out in triplicate by applying Beer’s law to the 
UV–Vis absorbance of the supernatant solutions obtained 
by filtration (see above). For the method to be accurate, we 
considered the contribution to the absorbance of sources other 
than variations in drug concentration (mainly the presence 
of Pluronic® F-68 [Sigma-Aldrich] and PBCA degradation 
products in the supernatant solutions) by subtracting the 
absorbance of the supernatant produced under the same 
conditions but without DOX.21–23
DOX incorporation to the PBCA NPs was expressed in 
terms of drug entrapment efficiency (%) and drug loading (%). 
These parameters were calculated as follows:
Drug entrapment 
efficeiency (%)
Mass of drug incorporated 
=
(mg)





Massof drug incorporated mg







In vitro release of doxorubicin from 
poly(butylcyanoacrylate) nanoparticles
The dialysis bag method was used in triplicate to subsequently 
determine the amount of DOX released from PBCA NPs 
after its incorporation. Concretely, this characterization was 
performed on the PBCA NPs with the highest drug entrapment 
efficiencies (Figure 1B), ie, ≈22.3% for the adsorption method 
and ≈49.3% for the entrapment technique. Phosphate buffered 
saline (PBS) (pH =7.4±0.1) maintained at 37.0°C±0.5°C was 
used as the release medium for all of the experiments. The 
dialysis bag (2,000 Da cutoff; Spectrum® Spectra/Por® 6 dialy-
sis membrane tubing, Spectrum Laboratories, Inc., Rancho 
Dominguez, CA, USA) retained the NPs and allowed the free 
DOX molecules to diffuse into the dissolution medium. About 
2 mL of a drug-loaded PBCA NP suspension (containing 
2 mg/mL of DOX) was poured into the bags (previously soaked 
in water for 12 h) with the two ends held by clamps. The bags 
were then placed in a conical flask containing 50 mL of the 
receiving phase (PBS, pH 7.4), which was stirred at 250 rpm. 
At predetermined times (0.08, 0.25, 0.50, 0.75, 1, 2, 3, 6, 12, 
and 24 hours), 3 mL samples of the receiving phase were 
withdrawn for UV–Vis analysis at 481 nm. An equal volume 
of PBS, maintained at the same temperature, was added to 
the release medium after sampling to ensure sink conditions.






Figure 1 Doxorubicin-loaded PBca NPs.
Notes: scanning electron microscope picture of PBca NPs (A). Scale bar: 150 nm. DOX entrapment efficiency (%) (B), and DOX loading (%) (C) values on the surface of 
(adsorption procedure, open symbols: □), and within (entrapment procedure, full symbols: ■) PBca NPs, as a function of the initial drug concentration (the lines are guides 
to the eye). release of previously entrapped (full symbols: ■) or adsorbed (open symbols: □) doxorubicin from PBca NPs as a function of the incubation time in PBs, at 
ph =7.4±0.1 and 37.0°c±0.5°c (D).
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles; PBs, phosphate buffered saline.
cell culture
The MCF-7 human breast cancer cell line (European Collection 
of Cell Culture) and E0771 mouse breast cancer cell line (iso-
lated from an immunocompetent C57BL/6 mouse and provided 
by Robin Anderson from Peter MacCallum Cancer Center, East 
Melbourne, Australia) were used. Both estrogen receptor-pos-
itive cell lines were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma-Aldrich) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) and 10 mM HEPES 
(4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid) buffer, 
then maintained in a monolayer culture at 37.0°C±0.5°C under 




Cells were seeded into 24-well plates (104 cells/well for MCF-7, 
1.5×104 cells/well for E0771) and incubated with increasing 
concentrations of free DOX (0.05–5.00 μM), DOX-loaded 
PBCA NPs (equal to 0.05–5.00 μM of free DOX) and blank 
PBCA NPs (ie, with no DOX loading, and at similar dilutions 
to drug-loaded NPs). Cytotoxic activity was assessed by deter-
mining the 50% inhibitory concentration (IC
50
) values obtained 
from the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide-based colorimetric assay (MTT assay). After 8, 24, and 
48 hours of incubation, 20 μL of an MTT solution (5 mg/mL of 
cell culture medium) was added to each well. After incubation 
for 4 hours at 37°C±0.5°C, the culture medium was removed, 
and the resultant formazan crystals were dissolved in 200 μL of 
dimethyl sulfoxide (DMSO). The absorbance of the converted 
dye, which is proportional to the number of viable cells, was 
measured at 570 and 690 nm using a Titertek Multiskan™ 
colorimeter (Flow Laboratories, Irvine, UK). The percentage of 
surviving cells was expressed as relative growth rates (RGR, %) 




Absorbance of the negativecontrol
(%) = ×100  (3)
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Intracellular uptake of doxorubicin
The intracellular distribution of free DOX and DOX derived 
from drug-loaded PBCA NPs was visualized by fluorescence 
microscopy. MCF-7 and E0771 cells were seeded into 8-well 
chamber slides (BD Biosciences, Erembodegem, Belgium) 
(5×103 cells/well) in 300 μL of DMEM. According to Li 
et al25 the cells were incubated with high doses of free DOX 
(10.0 and 43.1 μM) and DOX-loaded PBCA NPs (equal 
to 10.0 and 43.1 μM of free DOX) for different periods 
(from 1 to 24 h). A 100 nM solution of 4′,6-diamidino-2-
phenylindole, DAPI, (Invitrogen™, Thermo Fisher Scien-
tific, Waltham, MA, USA) was used for nuclear staining. The 
cells were then rinsed with PBS, mounted, and examined 
with fluorescent microscopy (Nikon Eclipse 50i microscope, 
Nikon Instruments Inc., Melville, NY, USA). DOX was 
excited at 570 nm and DAPI nuclear stains at 358 nm. 
In addition, FACScan (Becton Dickinson, San Jose, CA, 
USA) was used for the quantification of DOX incorporation 
by cells. Cells were seeded in 6-well plates (1.5×105 cells/
well) in 2 mL of DMEM. After short incubations with DOX 
and DOX-loaded PBCA NPs (for 0.5, 1, 1.5, 2, and 4 h), the 
cells were washed with PBS. They were then harvested with 
a solution of PBS-ethylene-diamine-tetraacetic acid (0.02%) 
(EDTA), transferred to universal screw cap tubes, centrifuged 
(600× g for 5 min), and washed twice with PBS. FACScan 
analysis was used to obtain the mean value of fluorescence. 
The increase in mean fluorescence (IMF, %) was calculated 
as follows:
 IMF








Parental MCF-7 cells (control) and MCF-7 cells treated 
with DOX-loaded PBCA NPs (25 μg/mL) were fixed with 
2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) 
at 25.0°C±0.5°C for 1 hour. Postfixation was performed 
at 25.0°C±0.5°C for 2 hours with 1% osmium tetroxide 
(OsO
4
) in cacodylate buffer (pH 7.2), and sections were then 
dehydrated in 100% ethanol before a final dehydration in 
propylene oxide. Samples were then embedded in Epon 812 
resin. Ultrathin sections were stained with uranyl acetate and 
lead citrate, and then analyzed by optical and transmission 
electronic microscopy (Hitachi H7000 transmission electron 
microscope, Tokyo, Japan).24
Tumor induction and treatment
Female C57BL/6 mice (Scientific Instrumentation Center, 
University of Granada) were used in the in vivo study. All 
mice (body weight: 25–30 g) were maintained in a laminar 
airflow cabinet placed in a room maintained at 37.0°C±0.5°C 
and 40%–70% relative humidity, with a 12-hour light/dark 
cycle under specific pathogen-free conditions. The study was 
approved by the Ethics Committee of the School of Medi-
cine (University of Granada) and performed according to its 
guidelines. Pilot experiments were previously conducted to 
determine the number of malignant cells for subcutaneous 
injection. After that, tumors were induced by subcutane-
ous injection of 5×105 E0771 cells into the left flanks of 
C57BL/6 mice. When the tumor was palpable, animals were 
randomly divided into four groups (n=10) corresponding 
to the treatments with saline solution (group I), free DOX 
solution (group II), blank PBCA NPs (with no DOX loading) 
(group III), and DOX-loaded PBCA NPs (group IV). The 
doses of DOX administered were 10 mg/kg of body mass in 
all of the formulations containing the antitumor drug. Each 
mouse was intravenously administered the formulation every 
3 days up to a total number of 5 times. Weights and deaths 
were carefully recorded throughout the period, and the 
tumors’ largest diameter a plus the second largest diameter b 
perpendicular to a was measured using a digital calliper. The 










Statistical analysis was performed by using the Student’s 
t-test (SPSS version 7.5, SPSS, Chicago, IL, USA). Data 
with P0.05 and P0.001 were considered significant and 
very significant, respectively. A Kaplan–Meier method was 
used to determine the probability of mice survival, and the 
log-rank test was used to compare the fraction of surviving 
mice between groups (α=0.05).
Results
Particle geometry and surface electrical 
properties
The synthesis of PBCA NPs following an emulsion/
polymerization method allowed, in agreement with previous 
studies, the formation of highly stabile spherical particles 
with a narrow colloidal size distribution (average diameter of 
135±20 nm with a polydispersity index of 0.071, Figure 1A); 





as such, they are well suited to parenteral administration.22,25 
DOX loading did not influence either the NP geometry or 
the quality of the nanoparticulate suspensions. Finally, PCS 
measurements after 1 month of storage at 4.0°C±0.5°C in 
water confirmed that the size of the particles did not change. 
In addition, there was no observation of the formation of 
bulky sediments or aggregates, NP aggregation or DOX 
precipitation, and/or release during this time period. There-
fore, if the (nano-)preparations were not used directly once 
prepared, they were kept under these storage conditions until 
used. Finally, the electrokinetic characterization of the PBCA 
NPs (≈0.1%, w/v aqueous suspension) (ζ=-3.6±0.2 mV, at 
pH 4, 25.0°C±0.5°C and 10-3 M KNO
3
) was in agreement 
with previous electrophoretic studies on PBCA NPs in which 
a negative surface charge was observed at pHs 3.26
Doxorubicin loading to 
poly(butylcyanoacrylate) nanoparticles
We first investigated the influence of the drug-loading pro-
cedure on the quantity of DOX incorporated by the PBCA 
NPs: drug entrapment within the PBCA (nano-)matrix, and 
DOX surface adsorption onto previously synthesized PBCA 
NPs (see above). Interestingly, compared with DOX adsorp-
tion onto the NP surfaces, both the entrapment efficiency (%) 
and the drug loading (%) were significantly enhanced when 
DOX was entrapped within the NP matrices, independent of 
the initial DOX concentration. For instance, when the initial 
drug concentration was 0.01 M, these parameters, respec-
tively, increased from 22.3%±2.4% and 3.6%±0.4%, when 
DOX was adsorbed onto the NP surface, to 49.3%±3.1% and 
14.8%±0.9%, when the drug was entrapped within the NP net-
work (Figure 1B and C). Finally, drug concentration positively 
influenced DOX incorporation to the PBCA NPs, for both of 
the drug-loading procedures employed (entrapment and sur-
face adsorption). In the case of the adsorption method, over 
the range of initial DOX concentrations from 10-5 to 10-2 M, 
the entrapment efficiency and drug loading values increased 
from 3.4%±0.8% and 0.006%±0.001% up to 22.3%±2.4% 
and 3.6%±0.4%, respectively. For the entrapment tech-
nique, the corresponding values rose from 7.2%±1.1% and 
0.022%±0.001% to 49.3%±3.1% and 14.8%±0.9%, respec-
tively, over the same initial DOX concentration range (10–5 to 
10–2 M). In any case, a tendency toward saturation at higher 
concentrations was apparent (Figure 1B).
Doxorubicin release from 
poly(butylcyanoacrylate) nanoparticles
DOX release from PBCA NPs at pH 7.4 and 37.0°C showed 
a biphasic, sustained process that was characterized by an 
initial rapid, burst phase (up to ≈37% and ≈64% drug released 
in 1 hour for the cases of DOX entrapment within NPs and 
surface adsorption onto NPs, respectively), followed by a 
more sustained release of the remaining DOX molecules 
over a period of 23 hours for DOX entrapment and 5 hours 
for surface adsorption (Figure 1D). Taking our results into 
consideration, we decided to perform all in vitro and in vivo 
antitumor studies using the PBCA NPs that had the high-
est DOX entrapment efficiency (ie, ≈49%, Figure 1B) and 
that were characterized by a sustained drug release profile 
(Figure 1D): therefore, we used DOX-loaded NPs that were 
synthesized by the entrapment procedure using a fixed initial 
drug concentration of 0.01 M.
cytotoxicity of doxorubicin-loaded 
poly(butylcyanoacrylate) nanoparticles
Before the antitumor tests, the toxicity of blank PBCA 
NPs (with no DOX loading) was investigated in MCF-7 
and E0771 cells. No significant differences were observed 
between the negative control and the cells exposed to increas-
ing concentrations of PBCA NPs (Figure 2). Thus, the lack of 
cytotoxicity of the PBCA NPs alone meant they could safely 
be used as drug carriers. On the other hand, the cytotoxicity 
of DOX-loaded PBCA NPs against MCF-7 breast carcinoma 
cells (IC
50
: 0.5 μM) was significantly greater than that of free 
DOX (IC
50
: 2 μM) (P0.001) after 8 hours of incubation. 
This difference between the IC
50 
of DOX-loaded PBCA 
NPs and free DOX could still be observed after 48 hours of 
incubation (Figure 3A). In addition, the IC
50
 of DOX-loaded 
Figure 2 In vitro cytotoxicity of PBca NPs in McF-7 and e0771 cell lines.
Notes: growth of McF-7 and e0771 cells was evaluated after 48 h of exposure to 
a wide range of PBca NP concentrations (0.1–5.0 μM). Data represented as the 
mean value ± sD of quadruplicate cultures.
Abbreviations: PBca NPs, poly(butylcyanoacrylate) nanoparticles; sD, standard 
deviation; h, hours; NPs, nanoparticles.
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Figure 3 In vitro cytotoxicity of DOX-loaded PBca NPs in McF-7 (A) and e0771 (B) cells. growth inhibition was evaluated after 8, 24, and 48 h exposure to DOX-loaded 
PBCA NPs in comparison with free DOX. The percentage of survival was determined by normalizing the absorbance of controls to 100%. Data represented as the mean 
value ± sD of quadruplicate cultures.
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles; DOX-NPs, DOX-loaded PBca NPs; rgr, relative growth rates; sD, standard 
deviation; h, hours.
PBCA NPs in E0771 cells was significantly lower than the 
IC
50
 of the free antitumor drug (P0.05). DOX loaded within 
PBCA NPs yielded an IC
50 
(0.2 μM) 15 times lower than 
that of free DOX (IC
50
: 3 μM) after 8 hours of exposure and 
21.7 times lower (0.06 μM) after 48 hours of exposure (free 
DOX IC
50
: 1.3 μM) (Figure 3B).
Distribution of doxorubicin-loaded 
poly(butylcyanoacrylate) nanoparticles
MCF-7 and E0771 cell lines treated with DOX-loaded 
PBCA NPs and free DOX at different times and concentra-
tions were visualized by fluorescence microscopy. At any 
given moment, DOX-loaded PBCA NPs induced a more 





intense fluorescence (in both cytoplasm and nucleus) than 
free DOX, suggesting a greater DOX uptake by malignant 
cells (incorporation into the nucleus) when drug molecules 
were loaded within/onto NPs (Figure 4). Both cell lines were 
characterized by a similar drug incorporation and intracel-
lular drug localization.
Facscan analysis of doxorubicin 
location inside cells
To evaluate drug accumulation inside the malignant cells, we 
conducted a fluorocytometric analysis during the first hours of 
the treatment (Figure 5). When MCF-7 cells were incubated with 
high doses of DOX-loaded NPs for 0.5, 1, 1.5, 2, and 4 hours, 
relative increases in fluorescence were observed (51.9%, 42.7%, 
50.6%, 33.1%, and 34.2%, respectively) in comparison with 
tumor cells treated with free DOX (Figure 5A). Qualitatively, 
similar results were obtained for E0771 cells when comparing 
DOX-loaded NPs and free DOX, where the relative increases 
in fluorescence after the same periods of exposure were 53.0%, 
29.4%, 26.7%, 35.8%, and 15.5%, respectively (Figure 5B). 
This finding could be the consequence of a greater and 
more rapid DOX uptake when the drug is encapsulated within 
the PBCA NPs. As a result, a higher DOX concentration within 







Figure 4 Fluorescence microscopy analysis of the intracellular presence of DOX in McF-7 (A) and e0771 (B) cells.
Notes: Fluorescence studies showed that the accumulation of intracellular DOX in cells treated with DOX-loaded PBca NPs was always greater than intracellular DOX 
accumulation in cells treated with free DOX. The images are representative of treatment with the highest and lowest concentrations of free DOX (a, b, c) and DOX-loaded 
PBca NPs (a′, b′, c′): a and a′, 43.1 μM for 1 h; b and b′, 10 μM for 1 h; c and c′, 10 μM for 24 h. all images are at a 40× magnification.
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles; h, hours; DaPI, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride.
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Figure 5 Fluorocytometric analysis of the intracellular presence of DOX in McF-7 (A) and e0771 (B) cells.
Notes: representative image of the Facscan analysis and mean values of untreated cells and cells treated with free DOX and DOX-loaded PBca NPs (DOX-NPs) at the 
highest concentration (43.1 μM) over a 4 h period.
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles; h, hours.
Ultrastructural changes in breast cancer 
cells treated with doxorubicin-loaded 
poly(butylcyanoacrylate) nanoparticles
MCF-7 cells were assessed using transmission electron 
microscopy to determine the nature of any ultrastructural 
changes. As shown in Figure 6, treatment with both free DOX 
and DOX-loaded PBCA NPs caused dramatic changes in the 
cell nucleus after 4 hours of exposure to the drug. However, 
only DOX-loaded PBCA NPs induced significant nuclear 
alterations even after just 1 hour of exposure. In addition, 
MCF-7 cells treated with DOX-loaded NPs showed higher 
levels of mitochondrial damage compared with cells treated 
with free DOX for the same period and at the same concen-
tration. Finally, neither of the treatments induced significant 
differences in other cytoplasm structures.
In vivo breast cancer growth suppression 
and mice survival
The potential of DOX-loaded PBCA NPs to improve in vivo 
tumor cell death rates was evaluated using subcutaneous 
E0117 tumor-bearing immunocompetent C57BL/6 mice. The 
intravenous administration of DOX-loaded NPs was able to 
induce a significant inhibition of tumor growth (Figure 7). 
In fact, tumor volumes of mice treated with DOX-loaded 
NPs were significantly smaller than those of control mice 
(P0.01). At the end of the in vivo study (day 33), tumor 
growth was inhibited by up to 40% in mice treated with DOX-
loaded NPs compared with mice treated with free DOX. The 
intravenous injection of blank NPs did not influence the typi-
cal growth of untreated control tumors. On the other hand, 
both treatments (free DOX and DOX-loaded NPs) permitted 





Figure 6 Ultrastructural analysis of McF-7 cells.
Notes: McF-7 parental cells showed a large nucleus and a light cytoplasmic complexion containing well-preserved organelles including mitochondria (A). Treatment with 
free DOX (43.1 μM for 1 hour) induced nuclear alteration (arrows) (B). however, exposure of McF-7 to DOX-loaded PBca NPs at the same concentration and for the 
same time period resulted in major damage to the nuclei and produced a large number of altered mitochondria with disrupted cristae (arrows) (C and D). all images are at 
a 2,000× magnification.
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles.
Figure 7 effect of DOX-loaded PBca NPs on the growth of subcutaneous tumors induced by e0771 murine breast cancer cells in immunocompetent c57Bl/6 mice.
Notes: (A) Tumor volume variation after treatments. The DOX-loaded PBCA NPs demonstrated a significant increase in tumor inhibition (*P0.01, compared with the 
control and blank NPs; **P0.05, compared with free DOX). Data represented as the mean ± seM (n=10). (B) representative gross appearance of tumors excised from mice 
that died during treatment with DOX and with DOX-loaded NPs after 9, 24, and 33 d plus tumors taken from untreated mice after the same time intervals.
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles; seM, standard error of the mean; DOX-NPs, DOX-loaded PBca NPs; PBca, 
poly(butylcyanoacrylate); NPs, nanoparticles.
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a greater survival in comparison with the control group and 
the blank NPs group. The Kaplan–Meier curve also showed 
a 0.2-fold increase in the fraction of surviving mice when 
treated with DOX-loaded NPs in comparison with mice 
treated with free DOX (Figure 8). However, this increase 
was not significant according to the log-rank test.
In vivo toxicity
Body weight of the mice was monitored as a clinical sign of 
the in vivo toxicity of the treatment. According to Figure 9, 
mice treated with blank NPs showed neither increased mor-
tality nor noticeable losses of body weight compared with 
the controls. In contrast, mice treated with free DOX and 
DOX-loaded PBCA NPs showed a significant loss in body 
weight compared with the controls (P0.001). Interest-
ingly, during the treatment administration period (15 days), 
the weight loss was statistically lower (P0.001) in mice 
treated with DOX-loaded PBCA NPs than in those treated 
with free DOX, suggesting that NPs decreased drug toxic-
ity. After withdrawing the treatment, both groups recovered 
their body weight, resulting in similar values at the end of 
the experiment (33 days).
Discussion
In the present study, we reported a DOX-loaded PBCA 
nanoparticulate system that demonstrated significantly more 
in vitro activity against breast cancer tumor cells than the 
free antitumor drug, doxorubicin, inducing a 40% relative 
decrease in in vivo tumor growth when administered intra-
venously. Furthermore, the polymeric nanocarrier was able 
to reduce systemic toxicity, at least throughout the duration 
of the treatment. These results suggest that PBCA NPs may 
improve the efficacy of DOX therapies against advanced 
breast cancers.
We have developed a reproducible synthesis procedure 
for the formulation of DOX-loaded PBCA NPs to target 
breast cancer cells. The synthesis methodology is based on 
the emulsion/polymerization of butylcyanoacrylate monomer 
in an aqueous solution.18,19 The procedure afforded the syn-
thesis of spherical, stable DOX-loaded NPs with a number 
average diameter 160 nm (Figure 1A). These relatively 
small particles are expected to facilitate the uptake and accu-
mulation of DOX by and within malignant cells. In fact, it has 
been stated that drug carriers ranging from 100 to 200 nm in 
size enter cancer cells by receptor-mediated endocytosis.27 
The optimum synthesis conditions were taken as those that 
yielded the highest drug entrapment efficiencies and drug 
loading values (Figure 1B and C). In detail, the drug entrap-
ment procedure yielded the best DOX loading values, as is 
generally the case when drug molecules are added to the 
cyanoacrylate monomer solution before NP formation. This 
is probably due to the difficulty experienced by the antitumor 
drug in breaking away from the growing polymeric (nano-)
network once it is entrapped within it.19 In addition, a strong 
interaction between DOX molecules and the growing PBCA 
network has previously been described during emulsion/
polymerization synthesis, a consequence of hydrogen bond 
formation between the drug’s ammonium groups and the 
PBCA’s cyano groups.28
Despite the fact that an attractive electrostatic interaction 
may exist between the positively charged drug molecules 
and the negatively charged polymeric surface, DOX load-
ing values (%) for the surface adsorption method can be 
considered relatively low (4%) (Figure 1C).29,30 In fact, the 
approximation of this hydrophilic chemotherapy agent from 
the aqueous phase to the hydrophobic NP surface is expected 
to be thermodynamically unfavorable (when considering the 
decimal logarithm of the partitioning coefficient at pH 5.8 in 





Regarding the initial drug concentration, a positive effect 
on drug vehiculization was observed upon increasing [DOX] 
in the aqueous solution, as has been reported previously 
with other drugs.19,22 We did not investigate the influence of 
either monomer or stabilizing agent concentrations on drug 
entrapment because no relevant effect had previously been 
reported.22,25,32,33
Figure 8 Kaplan–Meier curves of mice bearing subcutaneous breast tumors.
Notes: Data were analyzed according to the mice survival in each group (n=10). 
comparison between treatment groups was performed with the use of the log-rank 
test (P0.05).
Abbreviations: DOX, doxorubicin; DOX-NPs, DOX-loaded PBca NPs; NP, 
nanoparticle.





With respect to previously published investigations into 
the development of DOX-loaded poly(alkylcyanoacrylate) 
NPs, although it has been demonstrated that 80% of the 
drug used in DOX loading experiments can be associated 
with the NPs, the mean particle size of these nanoformu-
lations (ie, 270±30 nm) is greater than the one obtained 
when following the synthesis described in this contribution 
(ie, 135±20 nm).8 Thus, a more favorable biological fate 
of the targeted drug-delivery system can be expected for 
the case of the nanoformulation developed by our research 
group.
DOX release from PBCA NPs at pH 7.4 and 37°C exhib-
ited a biphasic, sustained profile (Figure 1D), characteristic 
of this polymer family, which could be a consequence of NP 
disintegration via surface erosion, drug diffusion through 
the polymeric matrix, or both.19,22,34,35 More specifically, the 
rapid drug release during the first phase could be due to the 
loss of DOX–molecules that are surface associated and/or 
poorly entrapped (only adsorbed to the surface pores). These 
molecules rapidly diffused into the incubation medium. On 
the contrary, DOX release during the slower second phase 
may correspond to the fraction of the drug that is embedded 
deeply within the PBCA (nano-)matrix and that must follow 
a longer diffusion path before release into the surrounding 
medium. Finally, the faster release of DOX that occurs when 
the drug is adsorbed onto the NP surface may well be due 
to the weak physisorption of the hydrophilic drug onto the 
hydrophobic PBCA surface.
In order to define the antitumor activity of DOX-loaded 
PBCA NPs, they were tested in human MCF-7 and mouse 
E0771 breast cancer cell lines. No toxicity has been reported 
for the PBCA NPs, thus indicating that they provide a safe 
method for transporting biomolecules within living systems, 
and that any cytotoxic effects were only due to the loaded drug 
molecules. Interestingly, DOX-loaded PBCA NPs induced a 
greater inhibition of cell proliferation than free DOX in both 
cell lines, and in only a very short exposure time (8 h). After 
48 hours, DOX-loaded NPs induced a significant decrease of 
the IC
50 
in MCF-7 and E0771 cells in comparison with free DOX. 
To date, no significant increase in the antitumor DOX activity 
using poly(alkylcyanoacrylate) NPs has been described. Pre-
viously, DOX-loaded poly(isohexylcyanoacrylate) (PIHCA) 
NPs demonstrated some benefit in terms of cell cytotoxicity.36 
Recently, Wohlfart et al37,38 reported a significant but lesser 
increase in DOX activity in 101/8 rat glioblastoma cells using 
DOX-loaded PIHCA NPs. Duan et al39 also demonstrated a sig-
nificant decrease in the IC
50
 of DOX-loaded PBCA NPs in rela-
tion to free DOX, but only when the NPs were surface modified 
with folic acid. The same authors demonstrated a reduction 
in the viability of MCF-7 cells using DOX-cyanoacrylate, 
thanks to the down-regulation of P-glycoprotein and to the 
coadministration of curcumin.40 Although the cytotoxicity of 
Figure 9 evolution of body weight of immunocompetent c57Bl/6 mice during and after treatment.
Notes: Weight of mice was measured every 3 d. During and after treatment, treatment with blank NPs did not induce significant weight losses compared with the controls. 
In contrast, treatment with free DOX and DOX-loaded PBCA NPs always induced a significant mouse body weight loss with respect to the controls (P0.001). however, 
the loss induced by treatment with DOX-loaded PBCA NPs was significantly lower (*P0.001) than the loss caused by free DOX. Data represented as the mean value ± 
sD (n=10).
Abbreviations: DOX, doxorubicin; PBca NPs, poly(butylcyanoacrylate) nanoparticles; d, days; sD, standard deviation; DOX-NPs, DOX-loaded PBca NPs.
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anthracyclines has been observed to increase when entrapped 
within PBCA NPs, the mechanism of modulation of this drug 
activity has not yet been determined. One possibility is the 
use of surfactants that can act upon resistant mechanisms or 
enhance the plasma membrane permeability.41,42 In fact, it has 
been proposed that the presence of Pluronic® F-68 (Sigma-
Aldrich) (a nonionic surfactant), which was used to synthesize 
the DOX-loaded PBCA NPs in the present study, may lead to 
an increased cytotoxicity.43,44
Fluorescence microscopy and flow cytometry analysis 
were employed in an attempt to explain the enhancement of 
DOX cytotoxicity when the drug was incorporated within/
on the surface of PBCA NPs. A greater DOX concentration 
was observed within malignant cells compared with the use 
of free DOX, thus suggesting that the NPs can improve drug 
incorporation into the cells. In fact, different intracellular 
concentrations and locations (nucleus or cytoplasm) have 
been reported when DOX is loaded within/on the surface 
of the NPs compared with the concentrations attained when 
using free DOX–this has been attributed to a simple diffusion 
or endocytosis process.45,46 Free DOX and DOX-loaded NPs 
predominantly situated themselves within the nucleus of both 
MCF7 and E0771 cells. However, when the antitumor drug 
was loaded in NPs, DOX also accumulated in the cytoplasm 
after a short period of exposure. Reasons justifying the dif-
ferent DOX accumulation profiles inside malignant cells are 
lacking. Some authors have hypothesized that the presence of 
surfactants (eg, Pluronic® F-68, Sigma-Aldrich) could alter 
the membrane transport proteins, thus enhancing drug entry 
into tumor cells.43,44 Whatever the reason, the higher DOX 
concentration inside MCF-7 cells (when it is delivered via 
loaded NPs) could explain the significant mitochondrial dam-
age and nuclear alterations observed through transmission 
electron microscopy. In fact, morphological and ultrastruc-
tural changes caused by DOX in H9C2 rat myoblast cells 
(chromatin clumping, swollen mitochondria, disruption of the 
nuclear membrane structure, and cytoplasm vacuolization) 
were directly associated with the drug concentration.47 The 
actual mechanism(s) that results in the significantly higher 
cytotoxicity of DOX-loaded PBCA NPs against MCF-7 and 
E0771 cells compared with the cytotoxicity of free DOX is 
not clear. It is known that, whereas the free drug enters cells 
by simple diffusion, drug-loaded NPs may provide a different 
cell entry mechanism such as endocytosis, pinocytosis, or 
phagocytosis, which is still under discussion.48,49 It has been 
suggested that drug-loaded NPs are too large to pass through 
both the plasma and nuclear membranes. Thus, the presence 
of the drug within the cell nucleus must occur only once it 
has been released from inside the NPs.50,51 The significant 
decrease in DOX IC
50
 values in our cell lines after treatment 
with DOX-loaded PBCA NPs could be explained by the 
greater degree of drug incorporation into the cell when the NP 
biodegrades in the endosome and releases the DOX before 
finally reaching the nucleus.51,52
On the other hand, when DOX-loaded PBCA NPs were 
administered to tumor-bearing mice, a significantly greater 
inhibition of tumor growth (40%) was obtained in comparison 
with free DOX. This observation represents a substantial 
improvement in drug activity against breast cancer tumors. 
Our results demonstrated a similar or greater breast cancer 
growth inhibition when compared with the literature.53–55 
In the latter case, for example, a triblock N-(2-hydroxypropyl)
methacrylamide (HPMA) copolymer loaded with DOX 
molecules has demonstrated a 26-fold increase in the IC
50 
of 
the drug against 4T1 mammary carcinoma cells, but a mere 
21.4% tumor growth inhibition compared with the free drug.56 
The in vivo results reported here for DOX-loaded PBCA 
NPs can be directly related to the greater in vitro effect of 
DOX-loaded NPs. However, the use of NPs by itself could 
increase the concentration of drug inside the tumor tissue, 
where an enhanced permeability and retention (EPR) effect 
and a low lymphatic macromolecular clearance exist.57 Fur-
thermore, one of our main findings was the lower toxicity 
induced by the DOX-loaded PBCA NP treatment in relation 
to treatment with free DOX. Following the work of Yang 
et al56 who reduced DOX toxicity using a block copolymer 
DOX conjugate, we assessed the fluctuation of mice body 
weight to determine the toxicity of the in vivo treatment. 
Our results showed a similar weight evolution for both 
untreated mice and mice treated with blank NPs. In contrast, 
a 15-day treatment with DOX-loaded PBCA NPs resulted in 
the DOX causing a significant body weight loss in relation 
to the controls. Interestingly, this weight loss of body mass 
was statistically lower (P0.01) with DOX-loaded PBCA 
NPs than free DOX, suggesting that loading DOX within/
onto NPs decreased its toxicity. After withdrawing the treat-
ment, body weight was recovered by both groups, being 
similar at the end of the experiment (33 days). In contrast, 
others’ studies showed no significant differences in mice 
body weight between treatments with DOX-loaded PBCA 
NPs and those employing free DOX, although for the case 
in reference both treatments were assayed in intracranial 
gliomas.58 However, despite the positive results obtained in 
terms of reducing tumor growth and drug toxicity, the treat-
ment schedule described here was not enough to ensure a 
clear and significant modulation in mouse survival – probably 





related to the relatively short treatment period. Nevertheless, 
the increased antitumor activity of DOX against breast cancer 
cells when loaded within/onto PBCA NPs could be used to 
reduce the therapeutic dose of the drug as part of a strategy 
to limit its side effects.
Certainly, other nanosystems for DOX release such 
as lipid vesicles or liposomes with a high biodegradabil-
ity and biocompatibility also offer advantages in breast 
cancer treatment.59 Strategies that include targeting ligands 
on DOX-loaded lipid vesicles, which are accessible by 
tumor acidification, have allowed the release of drugs after 
NP endocytosis. This system increased the percentage of in 
vitro cell death by almost threefold.60 In addition, in murine 
xenograft models, lipid vesicles with DOX-loaded pH-
triggered anti-HER2/neu cells showed a greater reduction in 
tumor volume compared with FDA-approved DOX-loaded 
vesicles.61 However, the clinical application of lipid vesicles 
or liposomes requires optimization in terms of both size and 
surface to resolve some of their disadvantages, such as their 
rapid renal clearance, recognition by the reticuloendothelial 
system, or low penetration in tumors. By contrast, polymeric 
NPs similar to those used here have already demonstrated a 
homogeneous size, a greater ability to solubilize hydropho-
bic drugs, a sustained release of the drug plus highly stable 
and customizable physicochemical properties, which means 
they will be accepted for clinical use in the near future.62 
Further assays involving both NP types will be necessary to 
obtain a quantitative improvement in the response of breast 
cancer patients.
Conclusion
We have reported the optimal preparation conditions required 
to synthesize DOX-loaded PBCA NPs suitable for parenteral 
administration. Compared with surface adsorption, DOX 
incorporation within the NP matrix during the polymerization 
process has led to greater drug loading values and a slower 
drug release profile. The preclinical in vitro results described 
here have demonstrated the efficacy of DOX-loaded NPs 
against human and mouse breast carcinoma cells, given the 
important reduction of the IC
50
. In vivo studies have shown 
that DOX-loaded NPs can induce a significant inhibition 
of tumor growth and that the use of PBCA NPs reduces 
DOX toxicity. These results suggest that PBCA NPs may 
be used to improve the efficacy of DOX therapies against 
advanced breast cancers. The greater antitumor activity of 
DOX-loaded PBCA NPs could be used to reduce the dose 
of DOX needed to obtain an adequate antitumor effect but 
with almost negligible toxicity.
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